Welcome to our dedicated page for EBR SYS SEC filings (Ticker: EBRCZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EBR Systems, Inc. filings document an emerging growth company’s financial updates, governance votes, and capital-structure changes. The company’s Form 8-K reports include preliminary operating results, commercial and clinical progress, annual and special meeting voting results, and amendments to its certificate of incorporation.
Proxy materials for EBRCZ describe director elections, equity plan matters, shareholder approvals, common stock proposals, CHESS Depositary Interests, and related governance procedures. The filing record also documents the company’s reverse stock split, security issuance ratifications, and recurring disclosure controls around unaudited preliminary financial information.
EBR Systems, Inc. is asking stockholders at a virtual special meeting to approve a reverse stock split, ratify prior securities issuances, and allow a potential adjournment to gather more votes. The reverse split would combine between 5 and 20 existing shares into 1 new share, with the exact ratio set later by the Board, and would not reduce the 600,000,000 authorized common shares. CHESS Depositary Interests will not be consolidated; instead, the CDI-to-share ratio will change so each CDI continues to reflect the same underlying value after the split.
Because the split reduces shares outstanding without changing authorized shares, the number of authorized but unissued shares would rise, giving the company more flexibility to issue equity in future financings. Stockholders are also asked to ratify the prior issue of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement so those securities are excluded from the 15% ASX Listing Rule 7.1 limit. As of the record date, 450,259,169 common shares (including CDIs) were outstanding and entitled to vote.
EBR Systems, Inc. filed a current report to share that it has issued a press release describing its commercial and clinical progress and preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company noted that the press release, dated January 12, 2026, includes early estimates only, which are unaudited and may change once normal closing and audit procedures are completed.
The press release, titled “EBR Announces Strong Q4 FY 2025 Commercial and Clinical Progress,” is furnished as an exhibit and is not deemed filed for liability purposes under securities laws, nor automatically incorporated into other securities filings unless specifically referenced.
EBR Systems, Inc. reported Q3 2025 results as it begins commercial rollout of its WiSE CRT System following FDA approval on April 11, 2025. Revenue reached $512,093, generating gross profit of $223,722. Operating expenses were $12.1 million (R&D $6.24 million; SG&A $5.86 million), resulting in an operating loss of $11.88 million and a net loss of $12.19 million for the quarter. For the nine months, revenue was $681,797 with a net loss of $34.71 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $70.40 million, including cash and equivalents of $12.64 million and short-term marketable securities of $55.72 million. Notes payable, net, were $40.73 million with maturity in 2027. Inventory increased to $11.17 million as production scaled. Stockholders’ equity was $38.65 million. Shares outstanding were 449,889,450 as of September 30, 2025; the company reported 449,994,658 outstanding as of November 12, 2025.